Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection

January 12, 2011

http://www.therapeuticsdaily.com/news/article.cfm?contentValue=753083 & contentTyp\

e=newsarchive & channelID=26

Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for

Thymosin Alpha 1 Injection

From the PharmaLive.com News Archive - Jan. 05, 2011

NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ -- Dongsheng Pharmaceutical

International Co., Ltd. (the " Company " ) (OTC Bulletin Board: DNGH) announced

today that it has obtained the exclusive sales rights of Thymosin Alpha 1

Injection in 19 provinces in China from Shanghai Biochemistry Pharmaceutical Co.

I.

The State Food and Drug Administration of China (the " SFDA " ) approved the

manufacturing permit of Thymosin Alpha 1 Injection for Shanghai Biochemistry

Pharmaceutical Co. I on June 29, 2010. Immediately after such approval, Shanghai

Biochemistry submitted the manufactured samples to the SFDA for quality check,

which is a necessary step to receive final approval for mass manufacturing. We

expect that the samples will pass the quality check in the next 3-6 months, at

which time Thymosin Alpha 1 Injection will be granted final approval for mass

manufacturing.

Thymosin Alpha 1 Injection is an immune modifier that has been proven to be

effective in the treatment of chronic hepatitis B, acute severe hepatitis,

adjuvant therapy for tumor and immuno compromised diseases. Thymosin Alpha 1

Injection has been admitted into the China National Basic Medicine Coverage

List, thereby making it more affordable to consumers and potentially increasing

its demand. In June 2010, Dongsheng commenced a marketing campaign for Thymosin

Alpha 1 Injection within its sales and distribution network, and the response so

far from potential customers has been promising.

Mr. Zhu XiaoDong, CEO of Dongsheng Pharmaceutical International, stated that,

" Thymosin Alpha 1 is a high value and high margin medicine. Obtaining exclusive

sales rights for this product in 19 provinces represents another milestone that

Dongsheng Pharmaceutical has accomplished since it went public in March 2010. "

About Dongsheng Pharmaceutical International Co., Ltd.

Headquartered in Chengdu, Sichuan Province, China, Dongsheng Pharmaceutical

International Co., Ltd. engages in pharmaceutical technology promotion, trading

and warehousing of traditional Chinese medicine and bio-chemistry products. The

Company sells prescription and non-prescription drugs and provides new medicine

research and development and drug registration services distributing to more

than 30 provinces in China and throughout Southeast Asia.

For more information, please visit: www.eappic.com

Forward-Looking Statements

Pursuant to The Private Securities Litigation Reform Act of 1995, the statements

in this press release that relate to the Company's expectations with regard to

the future impact on the Company's results from new products in development are

forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. These statements are subject to risks and

uncertainties. Words such as " expects " , " intends " , " plans " , " may " , " could " ,

" should " , " anticipates " , " likely " , " believes " and words of similar import also

identify forward-looking statements. Forward-looking statements are based on

current facts and analyses and other information that are based on forecasts of

future results, estimates of amounts not yet determined and assumptions of

management. You are urged not to place undue reliance on the forward-looking

statements, which speak only as of the date of this release since they involve

known and unknown risks, uncertainties and other factors which are, in some

cases, beyond our control and which could, and likely will, materially affect

actual results, levels of activity, performance or achievements. We assume no

obligation to publicly update or revise any forward-looking statements in order

to reflect any event or circumstance that may arise after the date of this

release, even if new information becomes available in the future. Additional

information on risks and other factors that may affect the business and

financial results of Dongsheng Pharmaceutical International Co., Ltd. can be

found in the filings of Dongsheng Pharmaceutical International Co., Ltd. with

the U.S. Securities and Exchange Commission.

SOURCE Dongsheng Pharmaceutical International Co., Ltd.

CONTACT: Dongsheng Pharmaceutical International Co., Ltd. at +1-201-898-0688

(US), +86-10-8858-0780(CHINA) or eappic@...

Web Site: http://www.eappic.com

January 12, 2011